TrialsgrambetaRCTs are beautiful

HPTN 083

2021

Cabotegravir for HIV Prevention in MSM and Transgender Women

In 4,566 cisgender MSM and transgender women at high risk of HIV, long-acting injectable cabotegravir every 8 weeks reduced HIV acquisition compared with daily oral TDF/FTC.

Result

Efficacy: Incident HIV infectionHR 0.34

Below 1 favours long-acting injectable cabotegravir every 8 weeks, above 1 favours daily oral TDF/FTC.

Event rates Long-acting injectable cabotegravir every 8 weeks 0.41 vs daily oral TDF/FTC 1.22 per 100 patient-years

Also reported: 66 % more effective.

Original publication
Subtopic
Long-acting PrEP
Design
Double-blind, double-dummy RCT
Relevance
Important: one of several pillars.
Source
Landovitz RJ, et al. N Engl J Med. 2021;385(7):595-608.doi 10.1056/NEJMoa2101016

Discussion & critique

Basis of the FDA approval of long-acting cabotegravir for PrEP, particularly impactful for populations with adherence challenges.

Discussed in podcasts